New insider activity at VolitionRX ( (VNRX) ) has taken place on October 15, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In a significant show of confidence, key executives at VolitionRX have made substantial stock purchases. President & CEO Cameron John Reynolds acquired 110,000 shares valued at $56,100. Director Timothy I. Still purchased 48,076 shares for $24,518, while Director Guy Archibald Innes bought 96,153 shares, amounting to $49,038. These transactions highlight the leadership’s strong belief in the company’s future prospects.
Recent Updates on VNRX stock
VolitionRx (VNRX) announced the pricing of an underwritten public offering involving 11.55 million shares of its common stock and warrants to purchase an equal number of shares. The offering, priced at 52 cents per share and warrant, is expected to close around October 14, subject to customary conditions. The company plans to use the proceeds for research, product development, clinical studies, commercialization, working capital, and potential strategic acquisitions. This move is part of VolitionRx’s broader strategy to leverage strategic partnerships and growth potential, as evidenced by recent agreements, including a co-marketing and services agreement with Hologic and a first human out-licensing deal for APS. These developments have contributed to a positive outlook on the stock, justifying buy ratings based on anticipated growth and strategic initiatives.
Spark’s Take on VNRX Stock
According to Spark, TipRanks’ AI Analyst, VNRX is a Neutral.
VolitionRX’s overall stock score is primarily impacted by its weak financial performance, characterized by negative profitability and cash flow issues. Technical analysis further indicates bearish trends, while valuation metrics are poor due to ongoing losses. The earnings call provided some positive developments, but concerns about revenue predictability and cash reserves remain significant.
To see Spark’s full report on VNRX stock, click here.
More about VolitionRX
YTD Price Performance: -26.98%
Average Trading Volume: 248,119
Technical Sentiment Signal: Strong Sell
Current Market Cap: $48.71M